Novo Nordisk (NYSE: NVO) Receives EU Approval for Wegovy® 48-Hour Controlled-Temperature Delivery
Key Developments Novo Nordisk (NYSE: NVO) achieved a regulatory milestone as its Wegovy® injection became the first GLP-1 weight-loss medication approved for 48-hour controlled-temperature delivery within the European Union. This regulatory approval underscores Wegovy®’s innovative formulation and potential to meet patient needs more effectively across varied delivery conditions. The approval is significant as it expands the practical uses for Wegovy®, allowing more flexibility in storage and transport, which could improve…
